Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, has closed a £2.14 million GBP seed funding round. The investment round was led by Parkwalk Advisors, with the University of Cambridge Seed Funds, Martlet Capital, and angel investors also contributing to the fundraise.